COEPMEDIUM SIGNALFINANCIAL10-K

COEP substantially increased total assets while meaningfully reducing liabilities, though operational losses deepened and cash position declined.

The company appears to have undergone a significant balance sheet restructuring, with assets growing substantially to $16.2M while cutting total liabilities by nearly 60% to $2.1M. However, the deteriorating operational performance with widening losses and declining cash reserves of $404K suggests potential liquidity concerns despite the improved balance sheet structure.

Comparing 2026-03-19 vs 2025-03-28View on EDGAR →
FINANCIAL ANALYSIS

COEP's financial profile shows a mixed picture with substantial asset growth to $16.2M and meaningful debt reduction, cutting total liabilities from $5.0M to $2.1M. Operating losses widened modestly to $13.0M while R&D expenses declined 45% to $1.3M, suggesting potential cost management efforts. The concerning element is the 55% decline in cash to just $404K, which combined with deteriorating operating cash flows could signal near-term liquidity pressures despite the stronger balance sheet position.

FINANCIAL STATEMENT CHANGES
Total Assets
Balance Sheet
+81.3%
$8.9M$16.2M

Asset base grew 81.3% — expansion through organic growth, acquisitions, or capital deployment.

Current Liabilities
Balance Sheet
-60.8%
$4.5M$1.8M

Current liabilities reduced — improved short-term financial position and working capital health.

Total Liabilities
Balance Sheet
-58.6%
$5.0M$2.1M

Liabilities reduced 58.6% — deleveraging improves balance sheet strength and financial flexibility.

Cash & Equivalents
Balance Sheet
-55.4%
$907K$404K

Cash declined 55.4% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Interest Expense
P&L
-50.7%
$218K$108K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

R&D Expense
P&L
-45.2%
$2.3M$1.3M

R&D spending cut 45.2% — could signal cost discipline or concerning reduction in innovation investment.

Operating Income
P&L
-29.7%
-$10.1M-$13.0M

Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.

Operating Cash Flow
Cash Flow
-29.4%
-$6.6M-$8.6M

Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.

LANGUAGE CHANGES
NEW — 2026-03-19
PRIOR — 2025-03-28
ADDED
Management s Discussion and Analysis of Financial Condition and Results of Operations 32 7A.
This report includes our audited consolidated financial statements as of and for the years ended December 31, 2025 and December 31, 2024.
The biopharmaceutical division focuses on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases.
Coeptis aims to advance treatment paradigms and improve patient outcomes through its cutting-edge research and development efforts.
The technology division focuses on enhancing operational capabilities through advanced technologies.
This division features AI-powered marketing software and robotic process automation tools designed to optimize business processes and improve overall efficiency.
The Company is continuing its development focus on both GEAR and SNAP-CAR and is considering prospective strategic partners for such development.
The global multiple myeloma market was $28.42B in 2024 and is expected to reach $47.04B by 2031 [Source: Data Bridge Market Research].
GEAR-NK is a pre-clinical in vitro proof-of-concept product..
In March 2025, the Company reached an agreement with Vy-Gen-Bio, Inc.
REMOVED
Management s Discussion and Analysis of Financial Condition and Results of Operations 33 7A.
This report includes our audited consolidated financial statements as of and for the year ended December 31, 2024.
This report also includes our audited consolidated financial statements as of and for the year ended December 31, 2023.
Our current business model is designed around furthering the development of our current product portfolio.
Our biopharmaceutical division is continually exploring partnership opportunities with companies that have novel therapies in various stages of development or companies with technologies that improve the way that drugs are delivered to patients.
We seek the best strategic relationships, which relationships could include in-license agreements, out-license agreements, co-development arrangements and other strategic partnerships in new and exciting therapeutic areas such as oncology, respiratory viral infections, and autoimmune diseases.
The Company is continuing its development focus on both GEAR and SNAP-CAR, and will be considering prospective strategic partners for such development.
Our intent is to seek regulatory approval in the 8 major markets comprised of the United States, the UK, Germany, Spain, France, Italy, China, and Japan.
The total multiple myeloma market size in these 8 countries was $16.27 billion in 2019 and is expected to increase modestly through 2030, according to DelveInsight.
GEAR-NK is a pre-clinical in vitro proof-of-concept product with in vivo evaluations planned for 2025.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →